Related Experiment Video
Updated: Jun 26, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
[Rivaroxaban: mode of action]
1Service d'immunologie-hématologie, Hôpital Lariboisière - Fernand Widal, Groupement hospitalier Nord, 2, rue Ambroise-Paré, 75475 Paris cedex 10, France. ludovic.drouet@lrb.aphp.fr
Annales Francaises D'Anesthesie Et De Reanimation
|February 3, 2009
Summary
Rivaroxaban, a direct factor Xa inhibitor, offers antithrombotic benefits but carries bleeding risks. Clinical trials are crucial for dose validation across all indications, as preclinical models are limited.
Area of Science:
- Pharmacology
- Hematology
Context:
- Rivaroxaban is the first registered oral anticoagulant with direct anti-Xa activity.
- Vitamin K antagonists (VKAs) are the current standard for preventing arterial thromboembolic events in atrial fibrillation, but have dosing and monitoring challenges.
Purpose:
- To assess rivaroxaban's efficacy and safety, considering its role as a first-in-class anticoagulant.
- To evaluate the necessity of clinical trials for dose determination in all foreseen indications, given limitations of preclinical models.
Summary:
- Direct targeting of factor Xa offers theoretical antithrombotic benefits with dose-dependent hemorrhage risk.
- Clinical trials are essential for validating doses, as in vitro and preclinical models have limitations.
- Prothrombin time is a sensitive routine test for monitoring rivaroxaban, potentially usable with standardization.
Impact:
- Highlights the importance of rigorous clinical trials for new anticoagulant classes.
- Suggests prothrombin time as a potential monitoring tool for direct anti-Xa inhibitors like rivaroxaban.
- Emphasizes the need for specific dose validation rather than extrapolation for rivaroxaban across indications.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Depolarizing Blockers: Mechanism of Action
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...